AAPL   319.10 (+0.36%)
MSFT   181.63 (-0.88%)
FB   227.40 (+1.03%)
GOOGL   1,438.99 (+0.38%)
AMZN   2,460.00 (+0.72%)
CGC   16.37 (-5.76%)
MU   47.19 (-1.50%)
GE   6.66 (+1.22%)
TSLA   867.77 (+3.92%)
AMD   53.24 (-1.04%)
T   30.99 (+0.00%)
ACB   13.40 (-4.90%)
F   5.70 (-0.18%)
GILD   76.03 (-2.31%)
NFLX   418.34 (-0.33%)
BAC   24.32 (+0.83%)
BA   147.87 (+1.38%)
AAPL   319.10 (+0.36%)
MSFT   181.63 (-0.88%)
FB   227.40 (+1.03%)
GOOGL   1,438.99 (+0.38%)
AMZN   2,460.00 (+0.72%)
CGC   16.37 (-5.76%)
MU   47.19 (-1.50%)
GE   6.66 (+1.22%)
TSLA   867.77 (+3.92%)
AMD   53.24 (-1.04%)
T   30.99 (+0.00%)
ACB   13.40 (-4.90%)
F   5.70 (-0.18%)
GILD   76.03 (-2.31%)
NFLX   418.34 (-0.33%)
BAC   24.32 (+0.83%)
BA   147.87 (+1.38%)
AAPL   319.10 (+0.36%)
MSFT   181.63 (-0.88%)
FB   227.40 (+1.03%)
GOOGL   1,438.99 (+0.38%)
AMZN   2,460.00 (+0.72%)
CGC   16.37 (-5.76%)
MU   47.19 (-1.50%)
GE   6.66 (+1.22%)
TSLA   867.77 (+3.92%)
AMD   53.24 (-1.04%)
T   30.99 (+0.00%)
ACB   13.40 (-4.90%)
F   5.70 (-0.18%)
GILD   76.03 (-2.31%)
NFLX   418.34 (-0.33%)
BAC   24.32 (+0.83%)
BA   147.87 (+1.38%)
AAPL   319.10 (+0.36%)
MSFT   181.63 (-0.88%)
FB   227.40 (+1.03%)
GOOGL   1,438.99 (+0.38%)
AMZN   2,460.00 (+0.72%)
CGC   16.37 (-5.76%)
MU   47.19 (-1.50%)
GE   6.66 (+1.22%)
TSLA   867.77 (+3.92%)
AMD   53.24 (-1.04%)
T   30.99 (+0.00%)
ACB   13.40 (-4.90%)
F   5.70 (-0.18%)
GILD   76.03 (-2.31%)
NFLX   418.34 (-0.33%)
BAC   24.32 (+0.83%)
BA   147.87 (+1.38%)
Log in

TSE:IMVIMV Stock Price, Forecast & News

C$4.07
-0.17 (-4.01 %)
(As of 06/1/2020 08:56 AM ET)
Add
Compare
Today's Range
C$3.99
Now: C$4.07
C$4.26
50-Day Range
C$2.15
MA: C$3.30
C$5.10
52-Week Range
C$1.98
Now: C$4.07
C$6.69
Volume158,700 shs
Average Volume131,638 shs
Market CapitalizationC$246.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. The company has collaboration and license agreement with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Read More
IMV logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-902-4921819

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$59,000.00
Cash FlowC$0.22 per share
Book ValueC$0.13 per share

Profitability

Miscellaneous

Employees51
Market CapC$246.05 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV (TSE:IMV) Frequently Asked Questions

How has IMV's stock been impacted by COVID-19 (Coronavirus)?

IMV's stock was trading at C$3.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMV stock has increased by 20.1% and is now trading at C$4.07. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IMV?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV.

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV.

How were IMV's earnings last quarter?

Imv Inc (TSE:IMV) released its quarterly earnings results on Monday, March, 30th. The company reported ($0.17) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.04. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. View IMV's earnings history.

What price target have analysts set for IMV?

4 analysts have issued 1 year target prices for IMV's stock. Their forecasts range from C$3.00 to C$9.00. On average, they anticipate IMV's share price to reach C$5.67 in the next twelve months. This suggests a possible upside of 39.2% from the stock's current price. View analysts' price targets for IMV.

Has IMV been receiving favorable news coverage?

Headlines about IMV stock have trended negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IMV earned a news impact score of -2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutIMV.

Who are some of IMV's key competitors?

What other stocks do shareholders of IMV own?

Who are IMV's key executives?

IMV's management team includes the following people:
  • Mr. Frederic Ors, Pres, CEO & Director (Age 45)
  • Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 54)
  • Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
  • Mr. Joseph Sullivan, Sr. VP of Bus. Devel.
  • Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations & Communications

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$4.07.

How big of a company is IMV?

IMV has a market capitalization of C$246.05 million and generates C$59,000.00 in revenue each year. IMV employs 51 workers across the globe.

What is IMV's official website?

The official website for IMV is www.imvaccine.com.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.